{"id":446568,"title":"Notice to stakeholders: Considerations regarding the proposed use of psilocybin mushrooms in clinical trials, or as a drug accessed through the Special Access Program (SAP) - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-01-03","captureTimestamp":"2026-01-03T12:16:31.897000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/notice-considerations-proposed-use-psilocybin-mushrooms-clinical-trials-special-access-program.html?wbdisable=false","snippet":"Notice to stakeholders: Considerations regarding the proposed use of psilocybin mushrooms in clinical trials, or as a drug accessed through the Special Access Program (SAP) May 6, 2022 Our file number: 22-105312-974 Purpose Health Canada is aware of the growing interest in the…","rawSnapshotUrl":"/api/snapshots/raw/446568","browseUrl":"https://replay.healtharchive.ca/job-6/20260103121631/https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/notice-considerations-proposed-use-psilocybin-mushrooms-clinical-trials-special-access-program.html?wbdisable=false#ha_snapshot=446568","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}